Modality
ERT
MOA
BiTE
Target
GIP-R
Pathway
PD-1/PD-L1
CKD
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
Jun 2022
→ May 2029
Phase 2Current
NCT06470760
2,643 pts·CKD
2022-06→2029-05·Recruiting
2,643 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-163.1y awayPh2 Data· CKD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Recruit…
Catalysts
Ph2 Data
2029-05-16 · 3.1y away
CKD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06470760 | Phase 2 | CKD | Recruiting | 2643 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BII-8315 | Biogen | NDA/BLA | CDK2 |